Brief: Merck Collaborates With Versant Ventures To Launch Saturnus Bio
Tue 14:38
BRIEF-Merck Collaborates With Versant Ventures To Launch Saturnus Bio June 23 (Reuters) - MERCK KGAA MRCG.DE:
COLLABORATES WITH VERSANT VENTURES TO LAUNCH SATURNUS BIO
MERCK HAS EXCLUSIVE RIGHTS TO ACQUIRE SATURNUS FOR A PRE-DETERMINED OPTION PAYMENT IN ADDITION TO SUCCESS-BASED EARNOUTS
RESEARCH-STAGE PARTNERSHIP ENTAILS A BUILD-TO-BUY DEAL STRUCTURE, INCLUDING AN UPFRONT PAYMENT OF $50 MILLION FROM MERCK TO FUND SATURNUS' RESEARCH ACTIVITIES
Further company coverage: MRCG.DE
(Gdansk Newsroom)
((Gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Merck KGaA
See all newsBrief: Merck Collaborates With Versant Ventures To Launch Saturnus Bio
Brief: Merck KGaA, Darmstadt, Germany, Collaborates With Versant Ventures To Launch Saturnus Bio
Brief: Pharma Mar's Partner Merck Submits Application For Lung Cancer Drug Zepzelca In Japan
Europe Research Roundup: ASML Holding, Douglas, Richemont
European shares lifted by miners and tech; Mideast in focus (updated)